PUBLISHER: Grand View Research | PRODUCT CODE: 1751198
PUBLISHER: Grand View Research | PRODUCT CODE: 1751198
The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.
Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.
The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.
Somatostatin Analogs Market Highlights